|
|
Post by mytakeonit on Jul 7, 2017 14:41:58 GMT -5
I have every stinking share still - lol. Averaged down again a good bit when we hit 1.86 (pre- R/S) told myself I'd sell those shares at 2.25...we'll we got to 2.23 and I still have them. A painful experience to be sure, however I see light at the end of the tunnel now and am optimistic that my pre-adcom 7.26 shares will def be green someday though the 5/1 really sucked. Did I think we'd be in this position in 2015 - Hell No.....but Afrezza IS a game changer and I'm def holding. July/Aug are going to be significant months for MNKD. I surely wish Mike and team the best of fortunes. And I've already got my 3K write-off in place from another stock from several years ago - FWIW slug ... you sound like a cry baby! Ha! I just hope that you didn't set sell limits on your steekng shares ... or you'll be crying again when we fly pass those stops and head for the 300 bagger. ?? Or, was it 400 bagger? Awww heck, let's just round it to 500 bagger and it'll be so much easier to remember. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 7, 2017 15:20:30 GMT -5
"One could argue that MNKD has had qualified and experienced people around them for many many years. That certainly didn't help the company in achieving success post FDA approval. Al Mann was a visionary and was successful by any standard, but he too failed to make Afrezza's potential success a reality. Matt devoted many years to MNKD and was just as qualified as Mike to be CEO. Frankly, I'm waiting for Mike Castagna to deliver on sales or meaningful improvements as CEO. I have been extremely unimpressed with his performance to date. Drive and passion, two attributes that he displays admirably, are not tools to measure success. Only results do that." With all due respect to Al, Matt, and Hakan and what they were able to accomplish, they did not have the skill set to market Afrezza and make it commercial. Al recognized that fact, hence the partnership with Sanofi. Matt did a great job keeping the company alive and hiring someone like Mike, but he is a finance guy and not a pharma marketer. Hakan is a scientist, not a marketer. As we have learned the hard way, launching a new drug, particularly one with mass market potential is highly complex, particularly considering all the hurdles involved - the FDA for label approval/change, endocrinologists, general practitioners, and the myriad of insurance companies and government agencies (e.g. Medicare). Marketing to those constituencies requires experience with all of them as well as a keen knowledge of and experience in direct to consumer pharma marketing. And just as Mike would likely not make a great finance guy or scientist, neither would Matt nor Hakan make great general managers in pharma marketing. I say this as someone with prior experience as a senior marketing manager in consumer products as well as a consultant to Fortune 500 companies. Despite that experience in market strategy, I would be woefully ill-equipped to launch a pharma brand like Afrezza. So I have been willing to give Mike a chance. But as we all know the clock has been and is ticking. I suppose I should have sold a while ago, but I didn't so at this point I have little choice but to let this ride out and see what happens - perhaps a miracle  Facts- This is a really good post. I personally would never go long on a bio stock ever again. I will trade MNKD in rare situations but I would short BIO before I am long. There are so many hurdles and MNKD has taught me I do not have the access to information needed to buy these types of stocks to go long on them. Warren Buffet stays away from this sector for a good reason. |
|
|
|
Post by nadathing on Jul 7, 2017 15:25:53 GMT -5
I've given up on the thought of ever making any money on this stock. I'd call it a win if I saw 50% of my investment returned. It was such a promising drug. Such a terrible waste. It makes me sad and angry. Al Mann made some serious business mistakes and it has destroyed the company. People can blame Hakan and Matt all day long, but they were hired by Al and left a mess by him.
|
|
|
|
Post by bones1026 on Jul 7, 2017 15:56:02 GMT -5
I've given up on the thought of ever making any money on this stock. I'd call it a win if I saw 50% of my investment returned. It was such a promising drug. Such a terrible waste. It makes me sad and angry. Al Mann made some serious business mistakes and it has destroyed the company. People can blame Hakan and Matt all day long, but they were hired by Al and left a mess by him. "It WAS a promising drug"?? Our bank accounts have taken a beating, but no matter what BP and their colluding partners do or say about the stock, there is nothing they can do to manipulate how the drug works..that's why we're all still here |
|
|
|
Post by sportsrancho on Jul 7, 2017 17:48:15 GMT -5
With all due respect to Al, Matt, and Hakan and what they were able to accomplish, they did not have the skill set to market Afrezza and make it commercial. Al recognized that fact, hence the partnership with Sanofi. Matt did a great job keeping the company alive and hiring someone like Mike, but he is a finance guy and not a pharma marketer. Hakan is a scientist, not a marketer. As we have learned the hard way, launching a new drug, particularly one with mass market potential is highly complex, particularly considering all the hurdles involved - the FDA for label approval/change, endocrinologists, general practitioners, and the myriad of insurance companies and government agencies (e.g. Medicare). Marketing to those constituencies requires experience with all of them as well as a keen knowledge of and experience in direct to consumer pharma marketing. And just as Mike would likely not make a great finance guy or scientist, neither would Matt nor Hakan make great general managers in pharma marketing. I say this as someone with prior experience as a senior marketing manager in consumer products as well as a consultant to Fortune 500 companies. Despite that experience in market strategy, I would be woefully ill-equipped to launch a pharma brand like Afrezza. So I have been willing to give Mike a chance. But as we all know the clock has been and is ticking. I suppose I should have sold a while ago, but I didn't so at this point I have little choice but to let this ride out and see what happens - perhaps a miracle Facts- This is a really good post. I personally would never go long on a bio stock ever again. I will trade MNKD in rare situations but I would short BIO before I am long. There are so many hurdles and MNKD has taught me I do not have the access to information needed to buy these types of stocks to go long on them. Warren Buffet stays away from this sector for a good reason. For years now facts has been my MNKD long board idol :-) When I grow up someday I want to be like her.. I only have one other bio which is EXAS. I don't like to own them. To hard. I understand the housing market. I'm riding LL to the moon:-)) |
|
|
|
Post by mbracket123 on Jul 7, 2017 18:13:25 GMT -5
Don't forget... Buffet used to swear off tech and now is huge investors in Apple etc.
|
|
|
|
Post by nadathing on Jul 7, 2017 18:57:59 GMT -5
I've given up on the thought of ever making any money on this stock. I'd call it a win if I saw 50% of my investment returned. It was such a promising drug. Such a terrible waste. It makes me sad and angry. Al Mann made some serious business mistakes and it has destroyed the company. People can blame Hakan and Matt all day long, but they were hired by Al and left a mess by him. "It WAS a promising drug"?? Our bank accounts have taken a beating, but no matter what BP and their colluding partners do or say about the stock, there is nothing they can do to manipulate how the drug works..that's why we're all still here Yes. It was a promising drug. Refill numbers don't lie. Refill numbers indicate it does not work for the majority who try it. It is not an insurance issue that causes people not to refill. You wouldn't fill a script you could not afford. You can say it is titration. Fine. Why hasn't that been resolved THREE years after approval. I believe the analyst who called it a niche drug was right. It may be a great drug for juvenile T1's. We may never know as the trials may not have even started and the company is out of money in 4-5 months. |
|
|
|
Post by nylefty on Jul 7, 2017 19:02:51 GMT -5
Total sales for the last four reported weeks: $1,044,000.
Total sales for the previous four weeks: $855,000.
Percentage gain: 22 percent
Despite all the doom and gloom being expressed on this board, I'll be happy if we can continue to increase sales by 22 percent every four weeks (and think the increases will be much better than that once the ad campaign picks up steam).
|
|
|
|
Post by sayhey24 on Jul 7, 2017 19:06:40 GMT -5
I am starting to get the feeling Nate Pile may just be right. In the near term I think a few of the international deals are real and at least one will bring significant money, enough to save MNKD. In the U.S. it will still take a few years for the technology and service companies to be in place to change how T2s are currently treated.
In the mean time in the U.S. MNKD needs to come up with a "correction" box with no spiro requirement, get every endo to prescribe it and sell it cheap enough insurance coverage is not needed. There is no excuse every T1 should not have afrezza for corrections.
|
|
|
|
Post by bioexec25 on Jul 7, 2017 19:08:50 GMT -5
Hi Nada, I'm involved with analyzing Trx leakage occasionally and it seems to me that if the majority were leaving due to efficacy there would be stories everywhere by now talking about how it doesn't work. Granted maybe there are and it's just me living in a bunker.
|
|
|
|
Post by sportsrancho on Jul 7, 2017 19:11:00 GMT -5
"It WAS a promising drug"?? Our bank accounts have taken a beating, but no matter what BP and their colluding partners do or say about the stock, there is nothing they can do to manipulate how the drug works..that's why we're all still here Yes. It was a promising drug. Refill numbers don't lie. Refill numbers indicate it does not work for the majority who try it. It is not an insurance issue that causes people not to refill. You wouldn't fill a script you could not afford. You can say it is titration. Fine. Why hasn't that been resolved THREE years after approval. I believe the analyst who called it a niche drug was right. It may be a great drug for juvenile T1's. We may never know as the trials may not have even started and the company is out of money in 4-5 months. No, they get the script and then the insurance says no. Then the reps, doctors, or MNKD cares have to help with writing the appeal letters to the insurance company's. The people, most, love it by that time and are really pissed they can't get it. I think MNKD has sent some of them some Afrezza in the mean time to hold them over..( not sure about that but it sounded like that on Twitter) I know Mike try's to reach out himself and help if they tweet to him:-) |
|
|
|
Post by wgreystone on Jul 7, 2017 19:19:58 GMT -5
"It WAS a promising drug"?? Our bank accounts have taken a beating, but no matter what BP and their colluding partners do or say about the stock, there is nothing they can do to manipulate how the drug works..that's why we're all still here Yes. It was a promising drug. Refill numbers don't lie. Refill numbers indicate it does not work for the majority who try it. It is not an insurance issue that causes people not to refill. You wouldn't fill a script you could not afford. You can say it is titration. Fine. Why hasn't that been resolved THREE years after approval. I believe the analyst who called it a niche drug was right. It may be a great drug for juvenile T1's. We may never know as the trials may not have even started and the company is out of money in 4-5 months. I think a typical patient visits the ENDO every 6 months, and gets a new prescirption and a refill. The script number has roughly equal NRX and RRX and has been in the same level (250 to 300) for a long long time. It properly implies the majority of the prescriptions are for existing Afrezza users. We really need to see a quick uptick of NRX numbers. So far the sales team can't drive new patients to try Afrezza. One big hurdle is insurance. |
|
|
|
Post by sayhey24 on Jul 7, 2017 19:58:19 GMT -5
Yes. It was a promising drug. Refill numbers don't lie. Refill numbers indicate it does not work for the majority who try it. It is not an insurance issue that causes people not to refill. You wouldn't fill a script you could not afford. You can say it is titration. Fine. Why hasn't that been resolved THREE years after approval. I believe the analyst who called it a niche drug was right. It may be a great drug for juvenile T1's. We may never know as the trials may not have even started and the company is out of money in 4-5 months. No, they get the script and then the insurance says no. Then the reps, doctors, or MNKD cares have to help with writing the appeal letters to the insurance company's. The people, most, love it by that time and are really pissed they can't get it. I think MNKD has sent some of them some Afrezza in the mean time to hold them over..( not sure about that but it sounded like that on Twitter) I know Mike try's to reach out himself and help if they tweet to him:-) Nadathing - do you understand what you just said? You said monomer human insulin, the exact same insulin secreted by the pancreas and which mimics phase 1 pancreatic release does not work in humans. Clearly, that can not be. The human body has been tuned over thousands of years to use the exact molecule afrezza is. In fact what does not work is metformin. In the biggest metformin study done to date patients had a 2 to 1 better outcome with diet and exercise than with metformin. We also know 70%+ of current metformin users are not meeting a 7.0 A1c target. In fact not one of the current T2 meds addresses the issue T2s have which is meal time sugar spikes. Only insulin can address this spike and hands-down afrezza is the best. I will say even though metformin is pretty much a failure as a treatment for diabetes all the other T2 meds are toxic and its a matter of time before most go the route of avandia. The reasons why afrezza does not blow away every other med is an educational issue; 1- PWD under-doses; 2 - PWD does not do follow-up doses on slow digesting meals; 3 - PWD does not properly inhale and gets a mouth full of powder; 4 - inhaler is used up side down; 5 - afrezza is kept in the refrigerator prior to use and clumps. There may be more but a big issue is "experienced T1s" have is they are on low carb/high fat diets. These diets are going to delay the sugar spike requiring second dosing. I think the education has gotten a lot better but I think Sports is spot on - cost and insurance are the reason for refill numbers but they seem to be improving too. |
|
|
|
Post by falconquest on Jul 7, 2017 21:08:47 GMT -5
"One could argue that MNKD has had qualified and experienced people around them for many many years. That certainly didn't help the company in achieving success post FDA approval. Al Mann was a visionary and was successful by any standard, but he too failed to make Afrezza's potential success a reality. Matt devoted many years to MNKD and was just as qualified as Mike to be CEO. Frankly, I'm waiting for Mike Castagna to deliver on sales or meaningful improvements as CEO. I have been extremely unimpressed with his performance to date. Drive and passion, two attributes that he displays admirably, are not tools to measure success. Only results do that." With all due respect to Al, Matt, and Hakan and what they were able to accomplish, they did not have the skill set to market Afrezza and make it commercial. Al recognized that fact, hence the partnership with Sanofi. Matt did a great job keeping the company alive and hiring someone like Mike, but he is a finance guy and not a pharma marketer. Hakan is a scientist, not a marketer. As we have learned the hard way, launching a new drug, particularly one with mass market potential is highly complex, particularly considering all the hurdles involved - the FDA for label approval/change, endocrinologists, general practitioners, and the myriad of insurance companies and government agencies (e.g. Medicare). Marketing to those constituencies requires experience with all of them as well as a keen knowledge of and experience in direct to consumer pharma marketing. And just as Mike would likely not make a great finance guy or scientist, neither would Matt nor Hakan make great general managers in pharma marketing. I say this as someone with prior experience as a senior marketing manager in consumer products as well as a consultant to Fortune 500 companies. Despite that experience in market strategy, I would be woefully ill-equipped to launch a pharma brand like Afrezza. So I have been willing to give Mike a chance. But as we all know the clock has been and is ticking. I suppose I should have sold a while ago, but I didn't so at this point I have little choice but to let this ride out and see what happens - perhaps a miracle I certainly don't disagree with your analysis but what was wrong with Matt (the finance guy) and Mike (the commercialization specialist) as a team? Unless they clashed rather than finding synergy, it would seem the best route was the previous management line up. Looking at it another way, we are in need of cash so we fire our finance guru and hire a salesman who has never been a CEO. Not saying it can't work but.....kinda seems like a hail Mary to me. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 7, 2017 23:13:58 GMT -5
It's been a hail Mary since SNY droppedMnkd
|
|
